Pharmalink International Ltd v Pharmazen Ltd

Link copied
Case Copied 41 min read

IN THE HIGH COURT OF NEW ZEALAND WELLINGTON REGISTRY

I TE KŌTI MATUA O AOTEAROA TE WHANGANUI-A-TARA ROHE

CIV-2025-485-000053

[2025] NZHC 2657

UNDER the Patents Act 2013 and Parts 20 and 22 of the High Court Rules 2016

IN THE MATTER OF

an appeal against a decision of the Commissioner of Patents

BETWEEN

PHARMALINK INTERNATIONAL LIMITED

Appellant

AND

PHARMAZEN LIMITED

First Respondent

COMMISSIONER OF PATENTS

Second Respondent

Hearing: 11 – 12 August 2025

Counsel:

GF Arthur KC for Appellant

JM Glover and JP Rogers for First Respondent

Judgment:

12 September 2025


JUDGMENT OF DOWNS J


This judgment was delivered by me on Friday, 12 September 2025 at 3 pm pursuant to r 11.5 of the High Court Rules 2016.

Registrar/Deputy Registrar

Solicitors/Counsel: Buddle Findlay, Auckland. James & Wells, Auckland. Crown Law, Wellington.

GF Arthur KC, Wellington. JM Glover, Auckland.

PHARMALINK INTERNATIONAL LTD v PHARMAZEN LTD [2025] NZHC 2657 [12 September 2025]

Table of Contents

The appeal  [1]

Appellate approach  [2]

Background  [3]

Synergy  [6]
Example 2  [9]
Example 3  [16]

Do examples 2 and 3 exhibit synergy?  [21]

Does the specification disclose the invention in a manner clear and complete enough for the invention to be performed by a person skilled in the art? Is the application supported by the material disclosed in

the specification?  [33]
Patient study (example 4)  [55]

Is amendment of a claim permissible on appeal?  [59]

Krill species  [63]
Mussel species  [65]
The definition of “about”  [66]

Is the invention novel?  [84]

It is obvious to combine the ingredients in the claimed ratios?  [96]
Summary of conclusions  [108]

Result  [109]

Costs  [110]

The appeal

[1]                 This judgment addresses a patent appeal. As is so often the case, the subject matter is technical. In what follows, I attempt to explain, as simply as possible, the applicable science. Some technical language is, however, unavoidable, including in relation to patent law.

Appellate approach

[2]                 An  appeal  in  this  context  is  a  rehearing   but,   as   appellant,   Pharmalink International Ltd1 must identify  error  on  the  part  of  the Commissioner of Patents or persuade me to a different conclusion from him.2


1      Pharmalink.

2      Austin, Nichols & Co Inc v Stichting Lodestar [2007] NZSC 103, [2008] 2 NZLR 141 at [16].

Background

[3]                 Pharmalink  applied  for  a  patent  in  relation  to  an  alleged  invention:    the anti-inflammatory effect of green-lipped mussel lipid extract with krill oil. Each ingredient has long been recognised as having anti-inflammatory properties. No one, however, had seemingly contemplated the two being combined or taken together to reduce inflammation beyond the sum of their parts. This introduces the key concept: synergy arises when ingredients produce just such an outcome. For example, an ingredient that reduced inflammation by two units with another that reduced it by three would  produce  a  synergistic   effect  if  together,  the  reduction  were  six  units.   A reduction of five units would be additive, not synergistic.

[4]                 Pharmazen Ltd3 opposed Pharmalink’s application on a multiplicity of grounds. The Assistant Commissioner4 dismissed several objections but upheld five, and…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pharmalink International Ltd v Pharmazen Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2025] NZHC 2657
Decision Date

CaseChat Overview and Summary

Pharmalink International Ltd appealed against a decision of the Commissioner of Patents declining Pharmalink's application for a patent in relation to an alleged invention: the anti-inflammatory effect of green-lipped mussel lipid extract with krill oil. Pharmalink's appeal succeeded in part and failed in part. Synergy was demonstrated by the examples to the relatively modest standard of plausibility. However, the specification did not disclose the invention sufficiently or support the breadth of the application. The claims were unclear, and amendment was not permissible on appeal. The alleged invention was novel. However, it contained no inventive step even though synergy was not obvious. This was because it was obvious, irrespective of synergy, to combine green-lipped mussel lipid extract and krill oil in the ratios claimed to maximise therapeutic effect. The appeal was therefore dismissed, and Pharmazen was awarded costs.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.